skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.12d (Release date: 2017-12-26)
SearchBox Top
SearchBox Bottom
Golvatinib (Code C82363)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Golvatinib

Definition: An orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growth factor receptor) and VEGFR-2 (vascular endothelial growth factor receptor-2) tyrosine kinases with potential antineoplastic activity. c-Met/VEGFR kinase inhibitor E7050 binds to and inhibits the activities of both c-Met and VEGFR-2, which may inhibit tumor cell growth and survival of tumor cells that overexpress these receptor tyrosine kinases. c-Met and VEGFR-2 are upregulated in a variety of tumor cell types and play important roles in tumor cell growth, migration and angiogenesis.

Display Name: Golvatinib

Label: Golvatinib

NCI Thesaurus Code: C82363 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C3642430  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
1,1-cyclopropanedicarboxamide, N-(2-fluoro-4-((2-(((4-(4-methyl-1-piperazinyl)-1-piperidinyl)carbonyl)amino)-4-pyridinyl)oxy)phenyl)-N'-(4-fluorophenyl)-
c-Met/VEGFR-2 Kinase Inhibitor E7050

External Source Codes: 
CAS Registry Number 928037-13-2 (see NLM ChemIDplus info)
FDA UNII Code 516Z3YP58E
PDQ Closed Trial Search ID 640626
PDQ Open Trial Search ID 640626 (check for NCI PDQ open clinical trial info)
UMLS CUI C3642430

Other Properties:
     Name Value (qualifiers indented underneath)
Chemical_Formula C33H37F2N7O4
code C82363
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name c-Met_VEGFR_Kinase_Inhibitor_E7050
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom